Genmab A/S
GMAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $6 | $1 | $6 |
| % Growth | -82.6% | 719.8% | -88.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $6 | $1 | $6 |
| % Margin | 94.3% | 93.8% | 94.1% | 94.8% |
| R&D Expenses | $0 | $2 | $0 | $3 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $1 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $3 | $0 | $4 |
| Operating Income | $0 | $2 | $0 | $2 |
| % Margin | 44.9% | 38.9% | 26.3% | 33.5% |
| Other Income/Exp. Net | $0 | $0 | $0 | $1 |
| Pre-Tax Income | $0 | $3 | $0 | $4 |
| Tax Expense | $0 | $1 | $0 | -$0 |
| Net Income | $0 | $2 | $0 | $4 |
| % Margin | 39.2% | 36.3% | 27.3% | 59.7% |
| EPS | 0.65 | 3.45 | 0.31 | 5.99 |
| % Growth | -81.2% | 1,012.9% | -94.8% | – |
| EPS Diluted | 0.65 | 3.42 | 0.31 | 5.99 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | $3 | $0 | $2 |
| % Margin | 49.2% | 48.4% | 37.1% | 36.6% |